Business
AstraZeneca's COPD Drug Advances
Late-stage trial results for AstraZeneca’s COPD drug have been announced, bolstering hopes of a blockbuster hit. The drug is expected to reach peak annual sales of over $5 billion.
Coverage timeline — 3 articles
MarketWatch
A carry trade unwind, a selldown in U.S. Treasury holdings and supportive fundamentals have all been cited
2026-09-08 11:42 UTC
STAT News
An experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market to itself.
2026-09-08 11:45 UTC
CNBC
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
2026-09-08 11:45 UTC